Germany Cardiac Resynchronization Therapy Market Report 2022 to 2030

Germany Cardiac Resynchronization Therapy Market

$ 3999

Germany Cardiac Resynchronization Therapy Market valued at $176 Mn in 2022, projected to reach $226 Mn by 2030 with a 3.2% CAGR. The global rise in heart failure cases, driven by aging populations and lifestyle-related cardiovascular diseases, is a key factor contributing to the expansion of the Cardiac Resynchronization Therapy (CRT) market. Currently, leading participants in this market include Abbott, Boston Scientific, Medtronic, Biotronik, Siemens Healthineers, St. Jude Medical, Sorin Group, Edwards Lifesciences, LivaNova, and Terumo.

ID: IN10DEPH443 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Dr. Medha Sansanwal

Buy Now

Germany Cardiac Resynchronization Therapy Market Executive Summary

Germany Cardiac Resynchronization Therapy Market valued at $176 Mn in 2022, projected to reach $226 Mn by 2030 with a 3.2% CAGR.

Cardiac resynchronization therapy (CRT) is a medical procedure that involves the use of a pacemaker to correct the heart's rhythm through a minor surgical intervention. The CRT pacemaker, implanted beneath the skin, coordinates the timing between the upper and lower heart chambers and synchronizes the left and right sides of the heart. This therapy is particularly important for individuals with heart failure, as it helps to address inadequate pumping and fluid accumulation in the lungs and legs due to the asynchronous beating of the heart's lower chambers. In some cases of severe heart rhythm issues, an implantable cardioverter-defibrillator (ICD) may be combined with CRT therapy. The CRT device connects wires from the pacemaker to both sides of the heart, employing biventricular pacing to ensure coordinated contractions and optimize overall heart function.

In 2021, Germany faced a serious cardiovascular health crisis with a high mortality rate of 48.1 deaths per 100,000 citizens due to acute heart attacks. The country had one of the highest rates of hospital admissions for congestive heart failure in the European Union, with 728 admissions per 100,000 population, which was linked to previous heart attacks. The prevalence of cardiovascular disease increased, indicating a growing health challenge, with a high number of individuals at risk. The classical risk factors like arterial hypertension, hypercholesterolemia, diabetes, and smoking were prevalent, highlighting the complexity of the cardiovascular health landscape. Germany reported 605,000 new myocardial infarctions and 200,000 recurrent attacks, emphasizing the urgent need for targeted interventions and public health strategies to address the multifaceted challenges posed by cardiovascular diseases in the country.

In June 2023, Biotronik achieved a significant milestone by receiving European regulatory approval to commence the first-in-human clinical trial for their groundbreaking "Orin Pro HF" implantable cardioverter-defibrillator (ICD). This innovative device is specifically designed to cater to the needs of heart failure patients, showcasing Biotronik's commitment to advancing cardiac care.

In March 2023, Abbott took a significant step forward in cardiovascular health by launching a clinical trial for their "Amplatzer Amulet Occluder LH." This minimally invasive device is implanted via a catheter to effectively close the left atrial appendage (LAA), thereby minimizing stroke risk in high-risk patients with specific pacemaker indications. Abbott's commitment to developing innovative solutions underscores their mission to address critical cardiovascular challenges with advanced and patient-friendly interventions.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Heart Failure: Heart failure is a significant public health issue in Germany, affecting around 1.5 Mn people. The prevalence of heart failure is expected to increase due to the aging population and the rise in risk factors such as obesity and diabetes. This growing patient population highlights the need for Cardiac Resynchronization Therapy (CRT) as a viable treatment option.

Collaboration and Innovation: The collaboration between healthcare providers, medical device manufacturers, and research institutions is promoting innovation in CRT technology and treatment strategies. This collective approach is accelerating market expansion by continuously improving patient care and outcomes.

Technological Innovations in CRT Devices: Recent technological advancements in Cardiac Resynchronization Therapy (CRT) devices, including minimally invasive implantation, precise multi-electrode leads, and remote monitoring capabilities, enhance the appeal of CRT therapy for patients and physicians. This heightened appeal is expected to drive market growth by addressing crucial factors influencing CRT device adoption.

Market Restraints

Economic Factors: Economic difficulties and limited financial resources may pose obstacles to the affordability of Cardiac Resynchronization Therapy (CRT) devices and procedures in Germany. This can affect both healthcare facilities and patients, creating challenges in accessing and providing necessary cardiac care. Economic constraints may limit the availability and accessibility of CRT technology, impacting the overall landscape of cardiac healthcare in the country.

Regulatory Obstacles: The regulatory environment in Germany presents obstacles for the CRT market, which could affect the prompt approval and introduction of innovative devices and technologies. Successfully overcoming these regulatory challenges may necessitate thoughtful strategic planning by market players aiming to establish themselves in the healthcare sector in Germany.

Restricted Insurance Benefits: Limited insurance coverage in certain areas poses a challenge for medical procedures like CRT, potentially hindering the broad adoption of these therapeutic interventions. This constraint could result in restricted accessibility and affordability for patients seeking cardiac resynchronization therapy in those regions.

Healthcare Policies and Regulatory Landscape

In Germany, healthcare policies and regulatory supervision concerning therapeutic medications are predominantly overseen by the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institute (PEI). BfArM, a federal agency operating within the Ministry of Health, is tasked with evaluating and endorsing drugs for the German market, ensuring their safety, efficacy, and quality. The PEI, serving as another regulatory authority, concentrates on advanced therapies and vaccines. Germany aligns with the regulations of the European Medicines Agency (EMA), contributing to a unified approach within the European Union. The Institute for Quality and Efficiency in Health Care (IQWiG) evaluates the effectiveness and cost-effectiveness of pharmaceuticals. The healthcare policies in Germany strive to strike a balance between facilitating access to innovative treatments and containing costs, establishing a robust regulatory framework to safeguard public health while promoting progress in medical fields.

Competitive Landscape

Key Players

Abbott
Boston Scientific
Medtronic
Biotronik
Siemens Healthineers
St. Jude Medical
Sorin Group
Edwards Lifesciences
LivaNova
Terumo

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Germany Cardiac Resynchronization Therapy Market Segmentation

By Product

CRT-Defibrillator
CRT-Pacemaker

By Age

Below 44 years
45-64 years
65-84 years
Above 85 years

By End-Users

Hospitals
Cardiac care Centres
Ambulatory Surgical Centres

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.